We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current 0RAM market cap is 498.88M. The company's latest EPS is NOK 1.0293 and P/E is 10.93.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 228.13M | 253.91M | 278.62M | 304.85M | 438.33M |
| Operating Income | 16.9M | 45.56M | 33.25M | -6.1M | 68.6M |
| Net Income | 66.2M | -96.95M | 24.87M | -4.72M | 45.64M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 504.17M | 321.92M | 333.15M | 407.21M | 398.58M |
| Total Liabilities | 90.77M | 49.51M | 57.38M | 133.95M | 75.76M |
| Total Equity | 413.4M | 272.41M | 275.77M | 273.26M | 322.82M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | 18.94M | -145.73M | 13.68M | -10.51M | 88.1M |
| Investing | -18.36M | -51.38M | -31.68M | -64.26M | -17.86M |
| Financing | -1.64M | -45.53M | -23.3M | 40.46M | -45.47M |
| Market Cap | 498.88M |
| Price to Earnings Ratio | 10.93 |
| Price to Sales Ratio | 1.14 |
| Price to Cash Ratio | 19.04 |
| Price to Book Ratio | 1.55 |
| Dividend Yield | - |
| Shares Outstanding | 44.35M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 11.25 |
| 52 Week Low | 11.25 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Vistin Pharma Asa |
| Address |
ostensjoveien 27 oslo 0661 |
| Website | https://www.vistin.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
